BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33675084)

  • 1. Selective Endothelial Hyperactivation of Oncogenic KRAS Induces Brain Arteriovenous Malformations in Mice.
    Park ES; Kim S; Huang S; Yoo JY; Körbelin J; Lee TJ; Kaur B; Dash PK; Chen PR; Kim E
    Ann Neurol; 2021 May; 89(5):926-941. PubMed ID: 33675084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic mosaicism in the MAPK pathway in sporadic brain arteriovenous malformation and association with phenotype.
    Gao S; Nelson J; Weinsheimer S; Winkler EA; Rutledge C; Abla AA; Gupta N; Shieh JT; Cooke DL; Hetts SW; Tihan T; Hess CP; Ko N; Walcott BP; McCulloch CE; Lawton MT; Su H; Pawlikowska L; Kim H
    J Neurosurg; 2022 Jan; 136(1):148-155. PubMed ID: 34214981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling.
    Fish JE; Flores Suarez CP; Boudreau E; Herman AM; Gutierrez MC; Gustafson D; DiStefano PV; Cui M; Chen Z; De Ruiz KB; Schexnayder TS; Ward CS; Radovanovic I; Wythe JD
    Circ Res; 2020 Aug; 127(6):727-743. PubMed ID: 32552404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS G12D or G12V Mutation in Human Brain Arteriovenous Malformations.
    Oka M; Kushamae M; Aoki T; Yamaguchi T; Kitazato K; Abekura Y; Kawamata T; Mizutani T; Miyamoto S; Takagi Y
    World Neurosurg; 2019 Jun; 126():e1365-e1373. PubMed ID: 30902772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain.
    Nikolaev SI; Vetiska S; Bonilla X; Boudreau E; Jauhiainen S; Rezai Jahromi B; Khyzha N; DiStefano PV; Suutarinen S; Kiehl TR; Mendes Pereira V; Herman AM; Krings T; Andrade-Barazarte H; Tung T; Valiante T; Zadeh G; Tymianski M; Rauramaa T; Ylä-Herttuala S; Wythe JD; Antonarakis SE; Frösen J; Fish JE; Radovanovic I
    N Engl J Med; 2018 Jan; 378(3):250-261. PubMed ID: 29298116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of treatment and therapeutic targets in brain arteriovenous malformation.
    Pan P; Weinsheimer S; Cooke D; Winkler E; Abla A; Kim H; Su H
    J Cereb Blood Flow Metab; 2021 Dec; 41(12):3141-3156. PubMed ID: 34162280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis and radiobiology of brain arteriovenous malformations: implications for risk stratification in natural history and posttreatment course.
    Achrol AS; Guzman R; Varga M; Adler JR; Steinberg GK; Chang SD
    Neurosurg Focus; 2009 May; 26(5):E9. PubMed ID: 19409010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosomal miR-3131 derived from endothelial cells with KRAS mutation promotes EndMT by targeting PICK1 in brain arteriovenous malformations.
    He Q; Huo R; Wang J; Xu H; Zhao S; Zhang J; Sun Y; Jiao Y; Weng J; Zhao J; Cao Y
    CNS Neurosci Ther; 2023 May; 29(5):1312-1324. PubMed ID: 36718590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of Brain Arteriovenous Malformation Through CRISPR/Cas9-Mediated Somatic Alk1 Gene Mutations in Adult Mice.
    Zhu W; Saw D; Weiss M; Sun Z; Wei M; Shaligram S; Wang S; Su H
    Transl Stroke Res; 2019 Oct; 10(5):557-565. PubMed ID: 30511203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide Reduces Hemorrhage of Brain Arteriovenous Malformations in a Mouse Model.
    Zhu W; Chen W; Zou D; Wang L; Bao C; Zhan L; Saw D; Wang S; Winkler E; Li Z; Zhang M; Shen F; Shaligram S; Lawton M; Su H
    Stroke; 2018 May; 49(5):1232-1240. PubMed ID: 29593101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutation-induced EndMT of brain arteriovenous malformation is mediated through the TGF-β/BMP-SMAD4 pathway.
    Xu H; Huo R; Li H; Jiao Y; Weng J; Wang J; Yan Z; Zhang J; Zhao S; He Q; Sun Y; Wang S; Cao Y
    Stroke Vasc Neurol; 2023 Jun; 8(3):197-206. PubMed ID: 36418055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK signaling represents a viable therapeutic vulnerability of KRAS-driven somatic brain arteriovenous malformations.
    Suarez CF; Harb OA; Robledo A; Largoza G; Ahn JJ; Alley EK; Wu T; Veeraragavan S; McClugage ST; Iacobas I; Fish JE; Kan PT; Marrelli SP; Wythe JD
    bioRxiv; 2024 May; ():. PubMed ID: 38766159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arteriovenous malformation in the adult mouse brain resembling the human disease.
    Walker EJ; Su H; Shen F; Choi EJ; Oh SP; Chen G; Lawton MT; Kim H; Chen Y; Chen W; Young WL
    Ann Neurol; 2011 Jun; 69(6):954-62. PubMed ID: 21437931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging pathogenic mechanisms in human brain arteriovenous malformations: a contemporary review in the multiomics era.
    Winkler EA; Pacult MA; Catapano JS; Scherschinski L; Srinivasan VM; Graffeo CS; Oh SP; Lawton MT
    Neurosurg Focus; 2022 Jul; 53(1):E2. PubMed ID: 35901735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reductions in brain pericytes are associated with arteriovenous malformation vascular instability.
    Winkler EA; Birk H; Burkhardt JK; Chen X; Yue JK; Guo D; Rutledge WC; Lasker GF; Partow C; Tihan T; Chang EF; Su H; Kim H; Walcott BP; Lawton MT
    J Neurosurg; 2018 Dec; 129(6):1464-1474. PubMed ID: 29303444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in Basic Research for Brain Arteriovenous Malformation.
    Barbosa Do Prado L; Han C; Oh SP; Su H
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.
    Koyama M; Kitazawa M; Nakamura S; Matsumura T; Miyazaki S; Miyagawa Y; Muranaka F; Tokumaru S; Okumura M; Yamamoto Y; Ehara T; Hondo N; Takahata S; Takeoka M; Miyagawa SI; Soejima Y
    Int J Oncol; 2020 Nov; 57(5):1179-1191. PubMed ID: 32901840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of intracranial aneurysms associated with arteriovenous malformations.
    Flores BC; Klinger DR; Rickert KL; Barnett SL; Welch BG; White JA; Batjer HH; Samson DS
    Neurosurg Focus; 2014 Sep; 37(3):E11. PubMed ID: 25175430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
    Dai X; Xia H; Zhou S; Tang Q; Bi F
    Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leptin plays a role in ruptured human brain arteriovenous malformations.
    Xie Q; Chen XC; Gong Y; Gu YX
    Acta Neurochir Suppl; 2008; 105():221-4. PubMed ID: 19066113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.